

中国临床前和毒性研究外包:现状分析与前景预测

Future Outlook of China Preclinical and Toxicology Outsourcing Market



Report Description

It has been well recognized in the global pharmaceutical industry that the R&D productivity of discovering a new medicine has been low. The high failure rate in various development stages has been the main factor that drives up the overall cost of drug discovery effort; whereas the severe toxicity and safety concerns have been the major causes of the high development failure. As all drug companies are vigorously controlling the R&D cost, the high failure rate has become a controlling factor for them to improve the efficiency and productivity of drug discovery and development. To reduce the overall cost of drug development, eliminating un-developable drug candidates and avoiding them being unnecessarily advanced to any late development stage have become critical to all drug companies. As such, all drug companies are now conducting extensive toxicology and safety pharmacology research for any drug candidates.

Although relatively young, the service capability of Chinese CROs in preclinical and toxicology research has been significantly improved in the recent years. As China possesses a number of advantages in preclinical and toxicology research, many drug companies are attracted by the significant benefits of conducting this type of research in the country.

To help these drug companies better understand the current state of this Chinese industry, the report “**Future Outlook of China Preclinical and Toxicology Outsourcing Market**” published by JZMed, Inc, a world renowned market research firm specialized in Chinese pharmaceutical industry, provides them with the unique insights into the current service capability and capacity of the Chinese preclinical and toxicology outsourcing industry.

The report revealed the current structural composition and the latest developments of the Chinese industry. By comparing the service capability and market size of the Chinese industry with its counterparts in the world, the report also provides a clear picture of where the Chinese industry currently stands in the global preclinical and toxicology outsourcing industry.

More importantly, by analyzing both growth drivers and resistors of the future development of the Chinese industry and the competitive landscape of the world preclinical and toxicology outsourcing industry, the report also provides the clear picture of the future development potential of this Chinese industry.

The report is a must-read book to all professionals in the industries of pharmaceutical, biotechnology, financial investment and outsourcing service that are interested in the China’s pharmaceutical outsourcing industry. It is also a valuable reference book to drug regulatory agencies and other government agencies that are involved in strategic planning for development of pharmaceutical industry in their own countries.

Scope of the Report

It has been well recognized in the global pharmaceutical industry that the R&D productivity of discovering a new medicine has been low. The high failure rate in various development stages has been the main factor that drives up the overall cost of drug discovery effort; whereas the severe toxicity and safety concerns have been the major causes of the high development failure. As all drug companies are vigorously controlling the R&D cost, the high failure rate has become a controlling factor for them to improve the efficiency and productivity of drug discovery and development. To reduce the overall cost of drug development, eliminating un-developable drug candidates and avoiding them being moved to any late development stage have become critical to all drug companies. As such, all drug companies are now conducting extensive toxicology and safety pharmacology research for any drug candidates.

Although relatively young, the service capability of Chinese CROs in preclinical and toxicology research has been significantly improved in the recent years. As China still possesses a number of advantages in preclinical and toxicology research, many drug companies are attracted to and become interested in conducting this type of research in the country. To help these drug companies better understand the current state of this Chinese industry, the report described this Chinese industry from four different aspects.

Chapter One analyzed in depth why toxicology and safety studies have become so important in the modern drug discovery and development, what drug companies' desire to improve their R&D efficiency and productivity and what the outsourcing service providers are doing to meet the requirements of the drug companies.

Chapter Two analyzed why it is the time to recognize China also as a favored outsourcing destination for preclinical and toxicology research and, based on the analysis, pointed out that preclinical and toxicology outsourcing might be the next hot wave in China following the current widespread small molecule drug discovery outsourcing in the country.

In Chapter Three, detailed description was provided to drug companies about what China currently has and what Chinese CROs currently can do in terms of their service capability and capacity.

In the Fourth Chapter, an in-depth analysis was conducted about all major drivers and resistors determining the future growth of the Chinese industry. Based on the analysis, the report then forecasted the market growth pace of the Chinese industry between 2010 and 2015 and the possible market value it could reach by 2015.

The report is a must-read book to all professionals in the industries of pharmaceutical, biotechnology, financial investment and outsourcing service that are interested in the China's pharmaceutical outsourcing industry.

About the Author

Jim J. Zhang, Ph. D.

Jim J. Zhang currently is president and managing director of JZMed, Inc., a leading market research company that specializes in the Chinese pharmaceutical, biotechnology and pharmaceutical outsourcing industries. Before founding the company, Jim worked for nine years with Albany Molecular Research, Inc. (AMRI), a US-based and currently one of the world largest CROs. During his tenure at AMRI Jim was responsible for managing and overseeing multiple drug R&D projects that involved the international cooperation of AMRI's multiple sites (USA, Singapore and Hungary). He played key roles in helping numerous pharma and biotech companies discover and develop a series of drug candidates that later entered preclinical and clinical development including advanced clinical trials. He was also the key contributor to the development of chemical production process for several developmental drugs. Prior to pursuing his Ph.D. program in the US, Jim worked for six years in a China-based CMO as process engineer and developed production process for a number of pharma products.

Jim's technical expertise spans from chemical process research and development to drug discovery and development for viral infection, cancer, chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Currently he holds 18 patents. He is also the principal author of 12 peer-reviewed research articles.

Jim has authored a series of research reports about Chinese pharmaceutical outsourcing industry. He was also invited by a number of market research firms such as Business Insights to author/co-author industry reports.

Jim received his master's degree in Chemical Engineering from East China University of Science & Technology (Shanghai), and his Ph.D. degree in Synthetic Organic Chemistry from the University of Iowa. He also received additional trainings in Medicinal Chemistry through working at Research Triangle Institute (Research Triangle Park, North Carolina).

Key Findings of the Report

- ◆ The Chinese pharmaceutical outsourcing industry has been growing in an exponential rate in the past decade. Most early established Chinese CROs almost all started with chemistry service only. However, after having practiced for a few years, a number of them have now also gained sufficient experience and skills in preclinical and toxicology research.
- ◆ The rapid development and growth of the Chinese preclinical and toxicology outsourcing industry is, to a large extent, contributed by the entrance of a number of multinational CROs that are attracted by the fast growth history and still huge future growth potential of the Chinese industry. Their presence has greatly enhanced the overall service capability of the Chinese industry.
- ◆ Currently, there have been about 65 CROs in total, including the China divisions/branches of those multinational CROs, in the Chinese preclinical and toxicology outsourcing service industry. Combined together, they provide a wide spectrum of services covering almost all areas of the preclinical and toxicology research. One of the key features of the Chinese service industry is that most Chinese CROs have non-human primates for *in vivo* efficacy testing and other pharmacological property studies, which have become more and more important in the modern preclinical and toxicology research.
- ◆ Most China-based CROs have brand new, state-of-the-art preclinical research facilities including animal vivaria. Currently, China has a capacity of more than one million square-foot animal space. About another one million square-foot animal facility is under construction.
- ◆ China has started implementing the GLP standard for preclinical and toxicology research since 2007, including the regulations on the use of animals in medical research. As the FDA gradually recognizes the Chinese GLP standard, more and more data generated in the laboratories of Chinese CROs are now accepted by the agency.
- ◆ Responding to the improvements, a large number of drug companies, both major pharma and small biotech, have outsourced their preclinical and toxicology research to China. After conducting drug discovery research in China for several years, the China R&D centers of many major pharma companies have generated a number of lead compounds in their pipelines which are ready to enter the next development stage. They are currently expanding their R&D focus in China along the value chain, from originally only discovery-focused research to now also including early development.
- ◆ Although the current outsourcing demands for preclinical and toxicology research service are still relatively soft in China (and in the globe as well) compared with those years before the financial crisis, in long term, these demands will be still strong. A

number of positive drivers, both globally and regionally and both internally and externally, all determine the anticipated fast future growth of the Chinese industry.

- ◆ Globally, as more major pharma companies will be implementing the strategy of networked partnership and as a key stage of drug development, outsourcing demands for preclinical and toxicology research will only become stronger and stronger. Similarly, outsourcing demands by small biotech companies will also become stronger as more and more of them now pursue virtual operation model, which determines that they will mostly rely on CROs to fulfill their R&D work.
- ◆ Regionally, as China will still possess a number of advantages even five to seven years from now in preclinical and toxicology research over many of its competitors in the world, drug companies from around the world will be attracted to conduct this type of research in the country.
- ◆ Internally, continually working with experienced multinational companies is steadily improving the skills and experience of Chinese CROs, which will in turn attract more drug companies to outsource to the country. The outsourcing service demand by the local domestic Chinese drug companies is also expected to grow rapidly in the near future as more and more Chinese drug companies are now embarked on innovative drug research.
- ◆ Externally, as many pharma companies have now recognized the power and usefulness of the large talent pool in China, conducting drug R&D directly in China can enhance their productivity. The fast development of the Chinese industry will also attract more multinational CROs to enter the Chinese market in the near future, which will further accelerate the development and growth of the Chinese industry.
- ◆ In the past several years China has been recognized as one of the best places in the world for small molecule drug discovery research. The country is currently also emerging as one of the most favored places for preclinical and toxicology research as well. It is therefore expected that the outsourcing service of preclinical and toxicology research will be the next wave in China. Major pharma companies will be looking for outsourcing or collaboration opportunities in China. They will also be implementing the networked partnership strategy in China through partnering with preferred local companies or research organizations.
- ◆ JZMed thus forecasted that the Chinese preclinical and toxicology outsourcing industry will likely grow in a CAGR of 27% for five years after 2010 and its market value will likely reach more than \$760 M by 2015.
- ◆ As the fast growth of the Chinese industry attracts more multinational CROs to enter the Chinese market, the current industry landscape of the Chinese preclinical and toxicology service sector will soon be changed as the competition will rise rapidly. For Chinese CROs to survive the anticipated competition, it is expected that more consolidations within the Chinese industry will take place in the very near future.

Key Features of the Report

- ◆ The report analyzed in depth and described in detail the current structural composition of the Chinese preclinical and toxicology outsourcing industry. Based on the broad and in-depth analysis, it is the first time ever that the report revealed the influence of the multinational service providers on the development and growth of the Chinese preclinical and toxicology outsourcing industry.
- ◆ It is also the first time that the report described in detail the current service capability and capacity of the Chinese industry including the successful identification of the best players of the Chinese industry, China-based CROs that are certified for GLP compliance or accredited by the international organizations for their facilities.
- ◆ It is the first time that the report provided a guide to world pharmaceutical and biotech companies that are interested in outsourcing to China of what China currently has and what Chinese CROs can do at this moment.
- ◆ It is also the first time that the report analyzed in depth the R&D activities of major pharma companies in China and the driving factors that attract them to China as well as the outsourcing strategies they are implementing in the country. Based on these analyses, the report then pointed out what the next outsourcing steps these major pharma companies will likely take in the Chinese market.
- ◆ The report analyzed and provided a detailed description of the latest development trends in the world preclinical and toxicology outsourcing industry with focus on the latest development of technologies, drug companies' new desires and the evolving services offered by global major CROs in the preclinical and toxicology outsourcing industry.
- ◆ The report also performed comparisons of the Chinese industry with its global counterparts in terms of their service capability and industry and market sizes. It provides a clear picture of where the Chinese industry currently stands in the world industry.
- ◆ By analyzing both in detail and in depth a series of drivers and resistors, the report also revealed how the Chinese industry will likely develop and grow in the near future and what market size it could reach as well as its possible market share in the global industry.
- ◆ One of the key features of the report is that it includes the detailed company profiles of the top 30 best players in the Chinese preclinical and toxicology outsourcing industry, including the detailed description of their service capability, features and experience. Besides, the company profile also contains the detailed information of their animal space capacity, features of their facilities and the disease models offered, in addition to their detailed contact information.

Your Questions Are Answered

The report provides detailed answers to a variety of questions many professionals are constantly asking about the Chinese preclinical and toxicology outsourcing industry:

- ◆ Why does toxicology study now become so important? How drug companies allocate their R&D budget to this part? How much is the current global toxicology research spending? How much of that is currently outsourced? How much toxicology outsourcing is from major pharma and how much from small biotech?
- ◆ What is the current market size of global preclinical and toxicology outsourcing? How much does Chinese market account in this global outsourcing sector?
- ◆ Why do pharma and biotech companies want to go to China for preclinical and toxicology outsourcing? What are their intentions of outsourcing to China?
- ◆ What advantages and disadvantages does China currently possess in preclinical and toxicology outsourcing? How to compare China's these advantages with its global counterparts? Will China still have such advantages in the following five to seven years?
- ◆ What are Chinese CROs' current service capability and capacity? Who are the best players in the Chinese industry? How do the world major CROs influence the development of this Chinese industry both in the past and in the future?
- ◆ Who are the Western CROs that provide this type of outsourcing service in China? How will their presence in China impact the development of the local Chinese CROs? How will this trend affect the future development path of this Chinese industry?
- ◆ Who are those world drug companies that are currently outsourcing preclinical and toxicology research to China? Why is it the right time to recognize China also as a favored outsourcing destination for preclinical and toxicology research?
- ◆ How will the Chinese preclinical and toxicology outsourcing market develop in the next five to seven years? How to compare it with the global preclinical and toxicology market in the same time period? How to compare the market size and service capability of the Chinese CROs in this sector with their global competitors including both Western CROs and Indian CROs?

Table of Contents

Scope of the Report

About Author

Executive Summary

- ◆ Growing importance of preclinical and toxicology research in drug discovery and development
- ◆ Preclinical and toxicology outsourcing nears mature in China
- ◆ Current service capability and capacity of Chinese preclinical and toxicology outsourcing industry
- ◆ Future outlook of preclinical and toxicology outsourcing in China

Chapter One: Growing Importance of Preclinical and Toxicology Research in Drug Discovery and Development

Summary

- 1.1 Introduction
- 1.2 Drug safety has become the bottleneck limiting drug R&D productivity
 - 1.2.1 Cost and efficiency of drug R&D have become key concerns to all drug companies
 - 1.2.2 In-depth analysis of the causes of high failure rate in drug R&D
 - 1.2.3 Reducing attrition rate and improving R&D productivity have become high priority to all drug companies
- 1.3 Changing models of drug R&D spending
 - 1.3.1 New trend: Less R&D budget but more positive results have become high priorities to all drug companies
 - 1.3.2 More R&D budget is being reallocated to preclinical and toxicology research
 - 1. Analysis of the cost structure of entire drug R&D process
 - 2. Reallocating more R&D budget to preclinical and toxicology research
- 1.4 Development of new technologies to more precisely probe toxicity of drug candidates
- 1.5 Global major CROs developing new outsourcing services
- 1.6 Evolving of new trends in preclinical and toxicology outsourcing
 - 1.6.1 New outsourcing models
 - 1. Contracting out a whole block of R&D functions
 - 2. Networked Partnership
 - 3. Open source innovation
 - 1.6.2 Destination of preclinical and toxicology outsourcing is shifting toward the East

Chapter Two: Preclinical and Toxicology Outsourcing in China Nears Mature

Summary

- 2.1 Introduction
- 2.2 Preclinical and toxicology outsourcing in China: A short history
- 2.3 Preclinical and toxicology outsourcing service is fast developing in China
 - 2.3.1 Rapid growth of the CRO pool in China
 - 2.3.2 Extremely fast growth of Chinese preclinical and toxicology outsourcing market
- 2.4 Rapid improvement of service capability of Chinese CROs in preclinical and toxicology research
- 2.5 China has formally established a regulatory body for preclinical research and is rapidly enhancing its capability
- 2.6 Growing importance of China to drug companies around the world for preclinical and toxicology research
 - 2.6.1 China's advantages in preclinical research
 - 1. Abundant animal species
 - 2. Large, well-trained workforce
 - 3. Cost effective advantage
 - 2.6.2 New development trends of preclinical and toxicology outsourcing in China – Entrance of growing numbers of multinational CROs: A series of case studies
- 2.7 Major pharma companies starting outsourcing preclinical and toxicology research in China
 - 2.7.1 Motivations of major pharma companies outsourcing preclinical and toxicology research to China
 - 2.7.2 Case studies: Latest examples of outsourcing and research collaborations between major pharma companies and Chinese companies/research organizations
- 2.8 Time to outsource preclinical and toxicology research to China nears mature

Chapter Three: Current Service Capability and Capacity of Chinese Preclinical and Toxicology Outsourcing Industry

Summary

- 3.1 Introduction
- 3.2 Current key players of Chinese preclinical and toxicology outsourcing industry
- 3.3 Service capability of China-based CROs
 - 3.3.1 Description of general service capability of China-based CROs
 - 1. General description of research scopes of modern preclinical and toxicology studies
 - a. Different focuses between preclinical and toxicology study
 - b. Main focuses of modern toxicology research
 - c. Difference and similarity between toxicology and safety pharmacology research
 - 2. General service capability of China-based CROs
 - 3.3.2 Service capability of China-based CROs in *in vitro/in vivo* ADME/Tox studies
 - 3.3.3 Service capability of China-based CROs in *in vivo* drug efficacy determination
 - 3.3.4 Service capability of China-based CROs in other related research areas

- 3.4 Current facility and capacity of China-based CROs
 - 3.4.1 General features of the facilities of China-based CROs
 - 3.4.2 Animal disease models offered by China-based CROs

Chapter Four: Future Outlook of Preclinical and Toxicology Outsourcing in China

Summary

4.1 Introduction

4.2 Future growth drivers of Chinese preclinical and toxicology outsourcing service industry

4.2.1 Internal drivers

1. China will still possess numerous advantages in preclinical and toxicology outsourcing before 2015
2. Improved service capability and quality
3. Government support
4. Entrance of world major CROs
5. Growing demands for outsourcing service by local domestic Chinese drug companies

4.2.2 External drivers

1. Strong demands by major pharma companies for preclinical and toxicology outsourcing
 - a. Globally, outsourcing demands for drug R&D especially preclinical and toxicology research service will become stronger – Analysis on latest outsourcing strategies implemented by major pharma companies
 - b. Regionally, outsourcing demands for Chinese preclinical and toxicology research service by major pharma companies will also become stronger
2. Strong outsourcing demands by small biotech companies for preclinical and toxicology research service

4.3 Future growth resistors

4.4 Forecast of future development patterns of Chinese preclinical and toxicology outsourcing industry

- 4.4.1 More competition
- 4.4.2 More consolidation

4.5 Future market growth forecast of Chinese preclinical and toxicology outsourcing industry

- 4.5.1 Future market growth forecast of Chinese preclinical and toxicology outsourcing industry
- 4.5.2 Comparison with global market
- 4.5.3 Comparison with Indian market

Company Profile: Top 30 China-based Best CROs Providing Preclinical and Toxicology Research Service

Appendix

Appendix I. Research Methodology
Appendix II. About JZMed, Inc.

List of Tables

- Table 1. Statistic distribution of failure rate in each development stage of drug R&D
Table 2. Factors contributing to high failure rates in drug development
Table 3. Global drug R&D spending in the past five years (2005 to 2009)
Table 4. Cost analysis of each development stage of drug R&D process
Table 5. Benefits of reallocating drug R&D budget to preclinical and toxicology research
Table 6. China-based CROs (or research organizations) accredited by AAALAC
Table 7. Classifications and features of China-based preclinical and toxicology CROs
(Including representative companies of each class)
Table 8. Current market value and its growth history of Chinese preclinical and toxicology outsourcing service industry
Table 9. Current market value and growth history of global preclinical and toxicology outsourcing service industry
Table 10. Growth of the market share of Chinese preclinical and toxicology outsourcing industry in the market value of global preclinical and toxicology outsourcing industry
Table 11. Representative Chinese organizations that have obtained GLP certificate from the SFDA
Table 12. China's advantages in preclinical and toxicology research
Table 13. Comparison of labor cost in various locations of the world (FTE rate)
Table 14. Comparison of feasibility and advantages between conducting small molecule drug discovery and preclinical/toxicology research in China
Table 15. List of top 30 best CROs in Chinese preclinical and toxicology outsourcing industry
Table 16. Founder classification of top 30 China-based best CROs
Table 17. Detailed description of research scopes of preclinical and toxicology studies
Table 18. Scope of modern *in vitro* and *in vivo* toxicology research
Table 19. Type of preclinical and toxicology research services offered by China-based CROs
Table 20. Key service features of each selected top CRO in China
Table 21. List of selected top China-based CROs and their detailed services in *in vitro/in vivo* DMPK/ADME studies
Table 22. List of selected top China-based CROs and their services in toxicology study
Table 23. List of selected top China-based CROs offering safety pharmacology service
Table 24. List of selected top China-based CROs and their services in *in vivo* efficacy testing
Table 25. List of selected top China-based CROs and their services in *in vivo* pharmacology
Table 26. List of China-based CROs and their services in *in vitro* biological assays
Table 27. List of China-based CROs providing bio-analytical services
Table 28. List of China-based CROs providing biomarker-related services
Table 29. Key features of the selected top China-based CROs' facilities

- Table 30. Current animal space capacity of selected top China-based CROs
- Table 31. List of China-based CROs possessing special animal disease models
- Table 32. Advantages China will still possess before 2015
- Table 33. Comparison of labor cost in countries around the world in the next seven years (FTE rate)
- Table 34. Comparison of cost saving (%) between China and other countries (at present and by 2015)
- Table 35. Market growth forecast of Chinese preclinical and toxicology outsourcing service industry
- Table 36. Market growth forecast of global preclinical and toxicology outsourcing industry
- Table 37. Forecasted growth of the market share of Chinese preclinical and toxicology outsourcing service industry in the same industry of the globe
- Table 38. Market growth forecast of Indian preclinical and toxicology outsourcing service industry and comparison with its Chinese counterpart

List of Figures

- Figure 1. Value chain of drug discovery and development
- Figure 2. Driving factors forcing the toxicology research moved to discovery and early development stages
- Figure 3. New technology development trends in preclinical and toxicology research
- Figure 4. Market growth trend of Chinese preclinical and toxicology outsourcing service industry
- Figure 5. Market growth trend of global preclinical and toxicology outsourcing service industry
- Figure 6. Key factors that facilitated Chinese preclinical and toxicology outsourcing service industry to weather the current financial crisis
- Figure 7. Key factors attracting drug companies to conduct preclinical and toxicology research in China
- Figure 8. Motivations of major pharma companies outsourcing preclinical and toxicology research to China
- Figure 9. Outsourcing strategies and practices currently implemented by major pharma companies in China
- Figure 10. Comparison of labor cost increase in China with other countries (from 2009 to 2015)
- Figure 11. Cost saving comparison (%) between China and other countries (in 2010 and 2015, respectively)
- Figure 12. Government plans to promote Chinese biopharma industry
- Figure 13. Impacts of the latest mergers and acquisitions between experienced multinational CROs and their Chinese counterparts on the future development of Chinese preclinical and toxicology outsourcing service industry
- Figure 14. Factors motivating major pharma companies to pursue more outsourcing in drug discovery, preclinical and toxicology research
- Figure 15. Current development trend of global small molecule drug discovery outsourcing

- Figure 16. Current R&D situation of major pharma companies in China
Figure 17. Analysis of the future outsourcing demands for Chinese preclinical and toxicology research service by major pharma companies
Figure 18. Forecasted market growth trend of Chinese preclinical and toxicology outsourcing service industry
Figure 19. Forecasted market growth trend of global preclinical and toxicology outsourcing service industry
Figure 20. Forecasted market share growth of Chinese preclinical and toxicology outsourcing industry in global preclinical and toxicology outsourcing industry
Figure 21. Forecasted market growth trend of Indian preclinical and toxicology outsourcing service industry

List of Case Studies

- Case Study 1. Drug R&D would not be that costly if failure rate could be reduced
Case Study 2. Biomarkers have become a hot outsourcing area in toxicology research
Case Study 3. Molecular imaging also becoming an important tool in preclinical as well as toxicology research
Case Study 4. Growing importance of epigenomics in assessment of drug safety and drug-induced toxicity
Case Study 5. Major CROs all embarked on biomarker service
Case Study 6. Charles River expanding discovery service
Case Study 7. Partnership formed to promote predictive toxicology service
Case Study 8. Alliance formed to develop drug toxicity screening assays
Case Study 9. Examples of major pharma companies increasingly utilizing external resources
Case Study 10. Examples of Western pharma companies outsourcing preclinical and toxicology research to Asian countries
Case Study 11. A unique class of workforce in China: Chinese returnees and its current state
Case Study 12. Frontier Biosciences entered Chinese market
Case Study 13. Bridge Lab established, expanded and eventually sold its China division
Case Study 14. Charles River entering Chinese market through acquiring a local Chinese CRO and currently aggressively looking for expansion
Case Study 15. Covance planning to offer preclinical outsourcing service in China
Case Study 16. Astra-Zeneca outsourcing preclinical and toxicology research to Chinese CROs
Case Study 17. Astra-Zeneca expanded discovery contract with BioDuro
Case Study 18. Pfizer signed *in vitro* ADME/Tox outsourcing contract with WuXi AppTec
Case Study 19. Johnson & Johnson forging close relationship with WuXi AppTec
Case Study 20. Attempted acquisition of WuXi AppTec by Charles River
Case Study 21. More recent merger and acquisition examples between Chinese CROs and their multinational counterparts
Case Study 22. Domestic Chinese drug companies increasingly collaborating with local CROs for drug R&D

- Case Study 23. Examples of pharma company outsourcing all drug discovery research
- Case Study 24. Global pharmaceutical outsourcing: An outlook of its future development
- Case Study 25. Major pharma companies have now recognized the power and usefulness of the large talent pool in China
- Case Study 26. More R&D-focused biotech companies adopting virtual operation model
- Case Study 27. Merger between two Chinese CROs
- Case Study 28. Alliance formed between two China-based CROs
- Case Study 29. Indian CROs' capability in preclinical and toxicology outsourcing service

About JZMed, Inc.

JZMed, Inc. (www.jzmedi.com) is a leading market research firm that specializes in Chinese pharmaceutical, biotechnology and outsourcing service industries. The company's primary focus is to provide intelligence services to global pharmaceutical and biotech companies to help them tap the resources in the Chinese pharmaceutical industry and explore the opportunities in the Chinese pharmaceutical market. Meanwhile, it also provides assistance to these companies to facilitate their entrance into the Chinese pharmaceutical market or collaborations with any Chinese companies. The company has a network of preferred pharma and biotech companies in China.

So far JZMed has provided this type of services to a variety of companies worldwide, including six of world top twenty pharma companies, more than ten biotech companies, more than fifteen professional outsourcing service companies (both CROs and CMOs) and more than twenty investment companies/banks including the largest ones in the Wall Street.

To Order

Information about the Report:

Author: Jim J. Zhang, Ph.D.
Publisher: JZMed, Inc.
Total number of pages: 188
Date published: October, 2010

Pricing:

For single user: \$2,895/PDF copy;
For department licensing: \$5,795 (PDF copy only)
For enterprise-wide licensing: \$8,695 (PDF copy only)

Readers interested in the report can contact JZMed, Inc. at order@jzmedi.com.

Report ordering can also be processed through PayPal, secured online payment, directly at the website of JZMed, Inc. (www.jzmedi.com). All major credit cards are accepted.